Inform Genomics, Inc., a Boston, Massachusetts-based developer of a novel platform of personalized medicine products for cancer supportive care and inflammatory diseases, has secured an undisclosed sum of funding.
Backers include a network of angel investors, including founders and directors.
Founded in 2010 and led by President & CEO Ed Rubenstein, M.D., Inform Genomics aims to develop transformational molecular diagnostic tests for individualized patient care and optimized drug development.
The company intends to use the funds to advance product development of ONPART™, its molecular diagnostic product designed to predict an individual patient’s risk of common side effects associated with widely prescribed chemotherapy regimens (colorectal, breast, lung, prostate or ovarian cancer).
FinSMEs
01/12/2011